Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Manuela Siebert"'
Autor:
Manuela Siebert
Publikováno v:
Revista Apotheke, Vol 4, Iss 1 (2018)
O ateliê̂ é o foco desta revista que pretende explorar esse espaço como lugar do fazer prático e teórico, e da experiência. Um lugar de ensino e aprendizagem, de trocas e reflexões. A ideia de explorar o ateliê̂ veio da necessidade de disc
Externí odkaz:
https://doaj.org/article/14e07c95196c4401a67dda419d8750f6
Publikováno v:
Blood. 140:8472-8473
Autor:
Sylvia von Mackensen, C. Wermes, Katharina Holstein, Susan Halimeh, Manuela Siebert, Wolf Hassenpflug, Martin Olivieri
Publikováno v:
Haemophilia
Background The worldwide pandemic spread of SARS-CoV-2 can lead to either respiratory infection or containment-associated isolation with possible higher impact on chronic diseases such as inherited bleeding disorders (IBD). The aim of the study was t
Publikováno v:
Blood. 138:1043-1043
Background: Heavy menstrual bleeding (HMB) is a common gynaecological problem and is the reason for 18-30% of gynaecological visits. In a European study in 4,502 women, 27.2% were diagnosed with HMB (Fraser et al., 2015). On the other hand, HMB is of
Publikováno v:
Hämostaseologie.
Publikováno v:
Science meets clinical practice.
Publikováno v:
Science meets clinical practice.
Publikováno v:
Blood. 134:3461-3461
Background: The child's diagnosis of a chronic genetic disease such as haemophilia is life-changing and impacts not only the child, but also the parents (Khair & Chaplin, 2016). Alloantibodies to factor concentrates occur in 25-30% previously untreat
Autor:
Randy E. Moore, Sylvia von Mackensen, G. Kappert, Hannelore Rott, Susan Halimeh, Manuela Siebert
Publikováno v:
Blood. 132:828-828
Background: Prophylactic substitution of clotting factor concentrates in haemophilia patients starting in early childhood, defined as primary or secondary prophylaxis, is nowadays the gold standard in developed countries. Prophylaxis compared to on-d
Publikováno v:
Blood. 132:3522-3522
Background: The development of inhibitors due to infused factor VIII (FVIII) remains a significant challenge in haemophilia treatment, particularly in previously untreated patients (PUPs). Inhibitors in PUPs usually develop within the first 50 exposu